Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor

Baxter International Inc. (NYSE: BAX) today announced a definitive agreement with Kamada Ltd. for exclusive commercial rights to GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid alpha1-proteinase inhibitor, in the United States, Australia, New Zealand and Canada.

GLASSIA™, which was approved by the FDA on July 1, 2010, is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency. AAT deficiency is an under-diagnosed hereditary condition that may result in early onset emphysema. Baxter expects to introduce GLASSIA™ in the United States during the fourth quarter of 2010, and will pursue distribution licenses for GLASSIA™ in the other countries for which it has obtained rights.

"The agreement with Kamada underscores Baxter's commitment to expanding the diagnosis of alpha1-antitrypsin deficiency by bringing new and innovative therapeutic options to Alpha-1 patients and their treating physicians," said Larry Guiheen, president of Global BioPharmaceuticals, Baxter BioScience.

The distribution agreement includes an upfront cash payment by Baxter of $20 million. The agreement also includes a provision under which Kamada has agreed, for a limited period of time, not to initiate or enter any discussions or agreements relating to the commercialization of GLASSIA™ in certain other geographies and for Kamada's investigational next-generation inhaled therapy. Under a separate license agreement, Baxter has been granted the right to process GLASSIA™ and will seek necessary regulatory approvals to enable it to do so. Also under this agreement, Baxter may make additional payments of up to $25 million related to the achievement of certain commercial milestones and the execution of a technology transfer related to the production of the therapy by Baxter, as well as royalties on product sales.

Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 24). Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor. News-Medical. Retrieved on April 06, 2020 from https://www.news-medical.net/news/20100824/Baxter-announces-definitive-agreement-with-Kamada-for-GLASSIA-alpha1-proteinase-inhibitor.aspx.

  • MLA

    Baxter International Inc.. "Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor". News-Medical. 06 April 2020. <https://www.news-medical.net/news/20100824/Baxter-announces-definitive-agreement-with-Kamada-for-GLASSIA-alpha1-proteinase-inhibitor.aspx>.

  • Chicago

    Baxter International Inc.. "Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor". News-Medical. https://www.news-medical.net/news/20100824/Baxter-announces-definitive-agreement-with-Kamada-for-GLASSIA-alpha1-proteinase-inhibitor.aspx. (accessed April 06, 2020).

  • Harvard

    Baxter International Inc.. 2019. Baxter announces definitive agreement with Kamada for GLASSIA alpha1-proteinase inhibitor. News-Medical, viewed 06 April 2020, https://www.news-medical.net/news/20100824/Baxter-announces-definitive-agreement-with-Kamada-for-GLASSIA-alpha1-proteinase-inhibitor.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial